Details of the Drug Reposition

General Information of This Drug (ID: DMN7H5K)

Drug Name
MK-7684   DMN7H5K

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Lung cancer DISCM4YA 2C25.0 Phase 3 [1]
------------------------------------------------------------------------------------
1 Phase 1 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Solid tumour/cancer DISZR48F 2A00-2F9Z Phase 1 [2]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT04738487) Vibostolimab (MK-7684) With Pembrolizumab as a Coformulation (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003). U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)